Tsingke Biotech Showcases Advanced Oligonucleotide Solutions at TIDES USA 2025

Tsingke Biotech Showcases Advanced Oligonucleotide Solutions at TIDES USA 2025



Tsingke Biotech, a prominent player in the biotechnology sector, recently made headlines at TIDES USA 2025, a leading international conference for oligonucleotide and peptide therapeutics held in San Diego from May 19 to 22, 2025. This significant event attracted numerous attendees and exhibitors dedicated to advancing research in nucleic acids and therapeutics.

As a repeat participant in this esteemed event, Tsingke Biotech presented its cutting-edge integrated model, dubbed "The Great Gene Factory." This innovative framework provides precision synthesis solutions that cater to a spectrum of needs spanning from early discovery phases to large-scale manufacturing processes. Tsingke's presence was marked by a strong emphasis on its core offerings, which included:

  • - End-to-End Synthesis Tools: Featuring the Syn-HCY series (with options such as 12P, 192P, and 768B), these tools facilitate high-throughput oligonucleotide production tailored for various applications including CRISPR, In-Vitro Diagnostics (IVD), and broader research demands.

  • - GMP Production System: Central to their offerings is the Syn-HL12 synthesizer, capable of scaling from 200 nmol to 12 mmol batches. This system is equipped with real-time monitoring capabilities for essential parameters such as UV, pH, and conductivity, ensuring precision and quality at every production stage.

  • - Comprehensive Application Coverage: Tsingke's synthesis solutions encompass a variety of therapeutic applications, including applications for ASO and siRNA therapeutics, gene editing techniques, mRNA vaccine development, and diagnostic probe synthesis. The versatility of their products resonates with current industry needs, facilitating advancements in multiple areas of biomedical research.

  • - Diverse Chemical Modifications: With over 300 different chemical modifications available and a robust supply chain for raw materials, Tsingke ensures consistency across batches, a critical component for reliable therapeutic developments.

Visitors to Tsingke's exhibit expressed particular admiration for the company’s automation features and its flexible modular equipment. This equipment is specifically designed to support the synthesis of high-purity, long-chain, and highly modified oligonucleotides, thereby meeting the increasingly complex demands of modern biopharmaceutical development.

Moreover, Tsingke's adept ability to integrate various reagents, cutting-edge instruments, and comprehensive services into a single platform attracted notable attention from pharmaceutical and biotech partners alike. This seamless integration not only enhances efficiency but also encourages collaborative efforts towards innovative solutions in the life sciences field.

Tsingke Biotech remains steadfast in its mission to empower life sciences by fostering innovation in therapeutic development. By building a world-class platform for nucleic acid synthesis, Tsingke is paving the way for new advancements that hold the potential to significantly impact medicine.

For interested parties or potential collaborators, Tsingke invites inquiries via their official communication channels. Explore more about their pioneering work and offerings by visiting their website at www.tsingke.com.

Tides USA 2025

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.